BioCentury
ARTICLE | Strategy

Repligen seeds a start-up

April 26, 1993 7:00 AM UTC

Repligen Corp. has provided an undisclosed amount of seed funding for Glycan Pharmaceuticals Inc., a new company founded by three of its senior scientists.

Glycan will develop small-molecule drugs targeted at a type of carbohydrate located on cell surfaces, heparan sulfate, which is important in a two-step process by which growth factors cause cells to divide. Growth factors are implicated in cancer, restenosis and other proliferative diseases such as psoriasis. ...